Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Crisugabalin and Metformin in Healthy Subjects
NCT04841720Phase 1Unknown
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Apr 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of crisugabalin besilate in diabetic peripheral neuropathy (DPN), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoints: Maximum Plasma Concentration, Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration and 2 more. Status: unknown.
02
Drugs
crisugabalin besilate
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT04841720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04841720.